Immunic (NASDAQ:IMUX) Trading Up 0.7% – Here’s What Happened

Immunic, Inc. (NASDAQ:IMUX)’s stock price shot up 0.7% on Monday . The company traded as high as $15.78 and last traded at $15.41. Approximately 358,011 shares were traded during mid-day trading, an increase of 73% from the average daily volume of 206,803 shares. The stock had previously closed at $15.30.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on the stock. Wall Street Zen lowered shares of Immunic from a “hold” rating to a “sell” rating in a research note on Sunday, April 19th. Lifesci Capital raised shares of Immunic to a “strong-buy” rating in a research note on Monday, May 4th. Stifel Nicolaus set a $25.00 target price on shares of Immunic and gave the stock a “buy” rating in a report on Thursday, April 16th. B. Riley Financial reduced their price target on shares of Immunic from $40.00 to $27.00 and set a “buy” rating on the stock in a research report on Friday, May 22nd. Finally, HC Wainwright reissued a “buy” rating and issued a $22.00 price target (up from $5.00) on shares of Immunic in a report on Thursday, April 30th. Three analysts have rated the stock with a Strong Buy rating, six have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Buy” and an average price target of $47.57.

Immunic Stock Performance

The firm has a market capitalization of $201.71 million, a P/E ratio of -2.65 and a beta of 1.37. The firm’s 50-day moving average is $12.67 and its 200 day moving average is $10.12.

Immunic (NASDAQ:IMUX) last released its earnings results on Wednesday, May 13th. The company reported ($1.08) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.71) by ($0.37). As a group, research analysts expect that Immunic, Inc. will post -4.57 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the company. Jane Street Group LLC raised its position in Immunic by 279.3% in the 1st quarter. Jane Street Group LLC now owns 207,401 shares of the company’s stock valued at $226,000 after buying an additional 152,726 shares during the last quarter. Vanguard Group Inc. boosted its position in Immunic by 5.3% during the 3rd quarter. Vanguard Group Inc. now owns 4,345,105 shares of the company’s stock worth $3,832,000 after acquiring an additional 219,957 shares during the last quarter. Squarepoint Ops LLC acquired a new position in Immunic during the 3rd quarter worth approximately $239,000. Two Sigma Investments LP bought a new position in shares of Immunic during the 3rd quarter worth approximately $52,000. Finally, Virtu Financial LLC bought a new position in shares of Immunic during the 3rd quarter worth approximately $99,000. 51.82% of the stock is currently owned by institutional investors.

About Immunic

Immunic, Inc is a clinical-stage biopharmaceutical company focused on developing novel oral therapies to treat chronic inflammatory and autoimmune diseases as well as certain cancers. The company’s research strategy centers on small-molecule immunology, aiming to offer targeted treatments with improved safety and tolerability profiles. By modulating key signaling pathways within the immune system, Immunic seeks to address underlying disease mechanisms and achieve durable therapeutic benefits for patients.

Immunic’s lead product candidate, vidofludimus calcium (IMU-838), is an oral selective dihydroorotate dehydrogenase (DHODH) inhibitor in Phase 2 clinical development for conditions including ulcerative colitis, Crohn’s disease and relapsing multiple sclerosis.